Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112359 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Bei Tong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Na…. Hauptthemen laut MEDLINE: Interleukin-2, Polyethylene Glycols, Immunotherapy, Interleukin-2 Receptor alpha Subunit. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
While Interleukin 2 (IL2) has the capability to activate both NK and T cells robustly, its limited in vivo half-life, considerable toxicity, and tendency to boost Treg cells pose significant challenges, restricting its widespread application in cancer therapy. In this investigation, we engineered a novel IL2 variant (IL2-4M-PEG) with reduced CD25 binding activity and an extended half-life by substituting amino acids associated with CD25 binding and implementing site-directed PEGylation. IL2-4M-PEG notably amplifies effector cells over Treg cells. Furthermore, our findings reveal that IL2-4M-PEG, characterized by an extended half-life, exhibits anti-tumor effects in a mouse model. Consequently, this innovative IL2 holds the potential for enhancing combined cancer therapies in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China.
- Department of Oncology, Nanjing Drum Tower Hospital, School of Life Science, Nanjing University, Nanjing, China.
- Department of Oncology, Nanjing Drum Tower Hospital, School of Life Science, Nanjing University, Nanjing, China; Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, Nanjing, China. Electr…
- Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China. Electronic address: dingxiao_qin@126.com.
- Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China. Electronic address: chenjian80@aliyun.com.
Förderung
- Jiangsu Provincial Key Research and Development Program
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Jiangsu Provincial Key Laboratory for the Research and Utilization of Plant Resources, Chinese Academy of Sciences
Zitieren
APA
Tong, B., Leong, S. G., Jian, T., Niu, G., Gai, Y., Meng, X., Lv, H., Dong, X., Ding, X., & Chen, J. (2024). Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112359
Vancouver
Tong B, Leong SG, Jian T, Niu G, Gai Y, Meng X, et al. Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112359
BibTeX
@article{Tong2024,
author = {Tong, Bei and Leong, Sirou Grace and Jian, Tunyu and Niu, Guanting and Gai, Yanan and Meng, Xiuhua and Lv, Han and Dong, Xianchi and Ding, Xiaoqin and Chen, Jian},
title = {Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112359}
}
EUVIMED